A Prospective, Open Label, Multi-Centre Treatment Research Initiative Exploring the Use of Rebif [Rm] in Subjects With Clinically Isolated Syndrome.
Phase of Trial: Phase III
Latest Information Update: 03 Apr 2012
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Demyelinating disorders; Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CIS-ON
- 03 Apr 2012 Company (Merck KGaA) added, actual patient number is 35 as reported by ClinicalTrials.gov.
- 03 Apr 2012 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 03 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.